CrushSCI.com
139.4Average days
142.5Median days
11Fastest days
221Longest days
3612025 publications

Paper Review Records

All Paper Review Records

24 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

145 days

M-CSF–driven TAM remodelling and actomyosin reactivation underlie BRAFi resistance in melanoma

Authors
Pol Sisó; Oscar Maiques; Judith Gracia-Bolívar; Christopher Ríos; Cristina Megino-Luque; Manel Albertí-Valls; Xavier Soria; Marta C. Sallan; Shukri Xalane; Lídia Sánchez-Moral; Yomara Morant; Maria Rosa Sarrias; Joan Verdaguer; Rosa Penin; Josep Maria Piulats; Núria Eritja; Susana Puig; Victoria Sanz-Moreno; Xavier Matias-Guiu; Rosa Maria Martí; Anna MaciàShow moreShow less
Affiliations
1. Oncologic Pathology Group, Biomedical Research Institute of Lleida – Dr. Pifarré Foundation, IRBLleida (ROR: 03mfyme49)Lleida, Spain; 2. Department of Experimental Medicine, University of Lleida, Lleida, Spain; 3. Cytoskeleton and Cancer Metastasis Group, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK; 4. Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, London, UK; 5. Department of Medicine, Division of Haematology and Oncology, Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, New York, USA; 6. Centre of Biomedical Research On Cancer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain; 7. Department of Medicine and Surgery, University of Lleida, Lleida, Spain; 8. Department of Dermatology, Hospital Universitari Arnau de Vilanova de Lleida, Institut de Recerca Biomèdica de Lleida (IRBLleida), University of Lleida, Lleida, Spain; 9. Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, London, UK; 10. Innate Immunity Group, Germans Trias I Pujol Research Institute (IGTP), Badalona, Spain; 11. Centre for Biomedical Research in Hepatic and Digestive Diseases (CIBERehd), Madrid, Spain; 12. Immunology Unit, Biomedical Research Institute of Lleida – Dr. Pifarré Foundation, IRBLleida (ROR: 03mfyme49), Lleida, Spain; 13. CIBER of Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain; 14. Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain; 15. Department of Medical Oncology, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain; 16. Melanoma Unit, Dermatology Department, University of Barcelona, Hospital Clínic & IDIBAPS (Institut d’Investigacions Biomèdiques August Pi I Sunyer), Barcelona, Spain; 17. Centro Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain; 18. Centre for Tumour Microenvironment, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, London, UK; 19. Department of Pathology and Molecular Genetics, Hospital Universitari Arnau de Vilanova de Lleida, Institut de Recerca Biomèdica de Lleida (IRBLleida), University of Lleida, Lleida, SpainShow moreShow less
Source PDF DOI Publisher page
169 days

Tetrandrine stabilizes NCOA4 to promote ferritinophagy-mediated ferroptosis and enhance antitumor immunity in NSCLC

Authors
Cong Xu; Xiaoyue Du; Zihan Xu; Zebo Jiang; Miaolin Zhu; Yulan Gu; Chen Peng; Shiying Zhu; Xin Wang; Bing Feng; Bowen Hu; Rujia Si; Qibiao Wu; Guoren Zhou; Feng Jiang; Shaodi Wen; Bo ShenShow moreShow less
Affiliations
1. Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Jiangsu, Nanjing, China; 2. Affiliated Zhuhai Hospital, Zhuhai Hospital of Integrated Traditional Chinese & Western Medicine, Southern Medical University, Zhuhai, China; 3. Oncology Department of Changshu Second Hospital, Changshu, China; 4. State Key Laboratory of Quality Research in Chinese Medicines and Faculty of Chinese Medicine, Macau University of Science and Technology, Taipa, Macau SAR; 5. Department of Oncology, Huaian People Hospital of Hongze District, Huaian, China; 6. DongTai People’s Hospital, Dongtai, ChinaShow moreShow less
Source PDF DOI Publisher page
103 days

Protein acylation in cancer: from regulatory networks to precision therapeutics

Authors
Zhixi Wei; Chi Ma; Jiajun Gao; Xinyi Zhang; Yiping Xu; Daoxin Ma; Wancheng Liu; Xiangling XingShow moreShow less
Affiliations
1. Department of Clinical Laboratory, Qilu Hospital of Shandong University, Jinan, PR China; 2. Department of Hematology, Qilu Hospital of Shandong University, Jinan, PR China; 3. Department of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, P.R. ChinaShow moreShow less
Source PDF DOI Publisher page
140 days

Tumor-infiltrating B cells evolve towards interferon-rich trajectories aligned with immunotherapy in melanoma

Authors
Katie Stoker; Roman Laddach; Lucy Booth; Silvia Crescioli; Oscar Maiques; Rebecca Adams; Jitesh Chauhan; Alexander Stewart; Dinethri Patel; Amanda Fitzpatrick; Yin Wu; Jenny L. C. Geh; Omar Salem; Alastair D MacKenzie Ross; Hawys Lloyd-Hughes; Sean Whittaker; Joseph Ng; Franca Fraternali; David Kipling; Deborah K. Dunn-Walters; Katie E. Lacy; Thomas J. Tull; Sophia Tsoka; Sophia N. KaragiannisShow moreShow less
Affiliations
1. St. John’s Institute of Dermatology, School of Basic and Medical Biosciences &, KHP Centre for Translational Medicine, Guy’s Hospital, King’s College London, London, UK; 2. Department of Informatics, Faculty of Natural, Mathematical and Engineering Sciences, King’s College London, London, UK; 3. Barts Cancer Institute, Queen Mary University of London, John Vane Science Building, London, UK; 4. School of Biosciences and Medicine, University of Surrey, Guildford, UK; 5. Department of Medical Oncology, Guy’s and St Thomas’ Hospitals, London, UK; 6. Breast Cancer Now Research Unit, School of Cancer and Pharmaceutical Sciences, King’s College London, London, UK; 7. Centre for Inflammation Biology and Cancer Immunology, School of Immunology & Microbial Sciences, King’s College London, London, UK; 8. St John’s Institute of Dermatology, Guy’s, and St. Thomas’ Hospitals NHS Foundation Trust, London, UK; 9. Department of Plastic Surgery, Guy’s and St. Thomas’ Hospitals NHS Foundation Trust, London, UK; 10. Randall Centre for Cell and Molecular Biophysics, School of Basic and Medical Biosciences, King’s College London, London, UK; 11. Department of Structural and Molecular Biology, Division of Biosciences and Institute of Structural and Molecular Biology, University College London, London, UK; 12. Faculty of Health and Medical Sciences, University of Surrey, Guildford, UKShow moreShow less
Source PDF DOI Publisher page
73 days

Beyond DNA damage: 3D tumor models and the integrin mechanobiology of radioresistance

Authors
Nils CordesShow moreShow less
Affiliations
1. OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; 2. Institute of Radiooncology - OncoRay, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany; 3. German Cancer Research Center, German Cancer Consortium, Partner Site Dresden, Heidelberg, Germany; 4. National Center for Tumor Diseases (NCT), Partner Site Dresden, German Cancer Research Center (DKFZ), Heidelberg, GermanyShow moreShow less
Source PDF DOI Publisher page
11 days

Transcriptional evidence of neuroendocrine cell plasticity beyond histological boundaries in lung neuroendocrine neoplasms: an in-silico analysis suggesting a progression model

Authors
Giuseppe Pelosi; Mauro Papotti; Riccardo Papa; Eleonora Duregon; Maria Gemelli; Sergio Harari; Angelica Sonzogni; Alice Laffi; Tommaso De Pas; Chiara Catania; Barbara Bassani; Fiorenza Lotti; Antonino Bruno; Paola Muti; Fabrizio BianchiShow moreShow less
Affiliations
1. Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; 2. Inter-Hospital Pathology Division, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) MultiMedica, Milan, Italy; 3. Department of Oncology, University of Turin, Turin, Italy; 4. Unit of Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) MultiMedica, Milan, Italy; 5. Department of Medical Sciences and Community Health, University of Milan, Milan, Italy; 6. Division of Pneumology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) MultiMedica, Milan, Italy; 7. Department of Pathology and Laboratory Medicine, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Istituto Nazionale Tumori, Milan, Italy; 8. Division of Medical Oncology, Humanitas Gavazzeni, Bergamo, Italy; 9. Laboratory of Innate Immunity, Unit of Molecular Pathology, Biochemistry, and Immunology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) MultiMedica, Milan, Italy; 10. Department of Biotechnology and Life Sciences, Laboratory of Immunology and General Pathology, University of Insubria, Varese, Italy; 11. Department of Biomedical, Surgical and Dental Health Sciences, University of Milan, Milan, Italy; 12. Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) MultiMedica, Milan, Italy; 13. Unit of Cancer Biomarkers, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, ItalyShow moreShow less
Source PDF DOI Publisher page

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.